Durable Continuous Transfusion Independence (TI) with Imetelstat in IMerge Phase 3 for Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents (ESAs)
Year: 2023
Type: conference-abstract
Source: Blood
Institutions: University Hospital Leipzig, Moffitt Cancer Center, Yale Cancer Center, Yale University, Hôpital Saint-Louis, Université Paris Diderot, University of Miami, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Hochschule für Musik Dresden, Azienda Ospedaliero-Universitaria Careggi, University of Florence
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4389232365